Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.
Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, McMurray JJV, Rossing P, Bakris G, Mahaffey KW, Mann JFE, Colhoun HM, Tuttle KR, Pratley RE, Perkovic V. Badve SV, et al. Among authors: gerstein hc. Lancet Diabetes Endocrinol. 2025 Jan;13(1):15-28. doi: 10.1016/S2213-8587(24)00271-7. Epub 2024 Nov 25. Lancet Diabetes Endocrinol. 2025. PMID: 39608381
Overweight and obesity among Israeli adolescents and the risk for serious morbidity in early young adulthood: a nationwide retrospective cohort study.
Zloof Y, Nitecki M, Simchoni M, Adar O, Tsur AM, Derazne E, Tzur D, Rotschield J, Braun M, Pinhas-Hamiel O, Fliss Isakov N, Milloh-Raz H, Nemet D, Dicker D, Moyal A, Scheuerman O, Beer Z, Braun M, Afek A, Gerstein HC, Batty GD, Chodick G, Twig G. Zloof Y, et al. Among authors: gerstein hc. Lancet Diabetes Endocrinol. 2024 Nov 15:S2213-8587(24)00287-0. doi: 10.1016/S2213-8587(24)00287-0. Online ahead of print. Lancet Diabetes Endocrinol. 2024. PMID: 39557052
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.
Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC. Del Prato S, et al. Among authors: gerstein hc. Cardiovasc Diabetol. 2024 Sep 28;23(1):352. doi: 10.1186/s12933-024-02432-7. Cardiovasc Diabetol. 2024. PMID: 39342203 Free PMC article. Clinical Trial.
Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
Punthakee Z, Hall S, McInnes N, Sherifali D, Tsiplova K, Kirabo FR, Ransom TPP, Harris SB, Lochnan HA, Sigal RJ, Ghosh M, Spaic T, Gerstein HC; REMIT‐IDegLira Collaborative Group. Punthakee Z, et al. Among authors: gerstein hc. Diabetes Obes Metab. 2024 Dec;26(12):5600-5608. doi: 10.1111/dom.15926. Epub 2024 Sep 6. Diabetes Obes Metab. 2024. PMID: 39239702 Clinical Trial.
454 results